Headlines Specialties Covid-19 Trending Feeds ASCO20 Videos

OncLive - Yale Cancer Center scientists have found that combining the targeted drug trastuzumab with chemotherapy significantly improves survival rates for women with a rare, aggressive...

OncLive - Pembrolizumab plus axitinib continued to significantly improve efficacy over sunitinib in patients with previously untreated metastatic renal cell carcinoma, according to updated results from...

OncLive - Anastasios (Tassos) Dimou, MD, discusses the progress made in the treatment of patients with ALK-positive lung...

OncLive - The FDA has issued a complete response letter to Merck and Eisai stating that it will not approve the applications that are seeking the...

  • The @US_FDA has issued a response letter stating that they will not approve the accelerated approval of pembrolizumab/lenvatinib for HCC because the combo does not provide evidence that it offers a meaningful advantage over other options. #hpbcsm https://t.co/REZmaYZDyi https://t.co/REZmaYZDyi

OncLive - Kamran A. Ahmed, MD, discusses the evolution of treatment for patients with breast cancer brain metastases, recent pivotal findings that have significantly improved survival...

OncLive - One of the major mysteries in treating patients with COVID-19 is the frequent development of blood clots that can subsequently damage their organs and...

OncLive - Melissa K. Accordino, MD, MS, discusses the findings of the PEARL trial in hormone receptor-positive, HER2-negative metastatic breast...

Postow Presents Progress Made in Melanoma

posted 5 hours

Shared 0 times

OncLive - Immunotherapy and BRAF plus MEK inhibition are the key players in the treatment of patients with melanoma, Michael Postow, MD, said in a presentation...

OncLive - OncLive serves as a connection to everything oncology, including interviews and videos from thought leaders and cutting edge articles and...